Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Recommendation of “Moderate Buy” from Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has earned an average rating of “Moderate Buy” from the fourteen analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and thirteen have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $45.10.

AVTX has been the subject of several research analyst reports. Wall Street Zen raised shares of Avalo Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Wedbush lowered their price target on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Leerink Partners assumed coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They set an “outperform” rating and a $38.00 price objective for the company. Finally, Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th.

Avalo Therapeutics Price Performance

Shares of Avalo Therapeutics stock opened at $19.34 on Tuesday. The business has a fifty day simple moving average of $19.03 and a two-hundred day simple moving average of $16.82. Avalo Therapeutics has a 1 year low of $8.65 and a 1 year high of $24.27. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -4.43 and a beta of 0.80.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, equities analysts anticipate that Avalo Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Mittie Doyle sold 1,450 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total value of $26,100.00. Following the completion of the sale, the insider directly owned 51,776 shares in the company, valued at $931,968. The trade was a 2.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System bought a new stake in shares of Avalo Therapeutics in the second quarter valued at about $196,000. Seven Fleet Capital Management LP grew its stake in shares of Avalo Therapeutics by 34.3% in the second quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock valued at $14,244,000 after acquiring an additional 196,882 shares in the last quarter. Braidwell LP bought a new position in Avalo Therapeutics during the second quarter worth about $30,107,000. Wellington Management Group LLP bought a new position in Avalo Therapeutics during the second quarter worth about $1,945,000. Finally, Bank of New York Mellon Corp bought a new position in Avalo Therapeutics during the second quarter worth about $1,897,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.